An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
AlloVir, Inc. (Nasdaq: ALVR), a clinical-stage cell therapy company, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be available from November 22 to December 2, 2021, accessible on the conference website and AlloVir's Investor section at ir.allovir.com. AlloVir focuses on restoring immunity against viral diseases, utilizing innovative allogeneic T cell therapies to treat patients with weakened immune systems. For more details, visit www.allovir.com.
Positive
None.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that the company will participate in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.
A pre-recorded fireside chat will be available from Monday, November 22 to Thursday, December 2, 2021, on the conference website and on the Investors & Press section of the AlloVir website at https://ir.allovir.com.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter or LinkedIn.
When will AlloVir participate in the Piper Sandler Virtual Healthcare Conference?
AlloVir will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021.
Where can I find AlloVir's fireside chat?
AlloVir's pre-recorded fireside chat will be available on the conference website and on AlloVir's Investor section at ir.allovir.com.
What is the focus of AlloVir's therapies?
AlloVir focuses on restoring immunity against life-threatening viral diseases using allogeneic T cell therapies for patients with weakened immune systems.
What is AlloVir's stock symbol?
AlloVir's stock symbol is ALVR.
What kind of company is AlloVir?
AlloVir is a clinical-stage cell therapy company specializing in treatments for viral diseases in patients with compromised immune systems.
